An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoNZ-804, a new oral drug, stops SARS-CoV-2 replication in animal models.Unlike current treatments, it’s safe, low-cost, and has a high barrier to resistance.#Treatment#NZ-804·cell.com·Nov 8, 2024An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
